Concepedia

Author

Raja Velagapudi

United States Food and Drug Administration

Also Known As

R VELAGAPUDI, R Velagapudi, R. B. VELAGAPUDI, R. Velagapudi, R.B. Velagapudi, Raja B. Velagapudi, Raja Velagapudi

22

Publications

836

Citations

13

H-Index

32

Concepts

All Affiliations

United States Food and Drug AdministrationDana-Farber Cancer InstituteSpring Valley HospitalUniversity of LisbonPharmo Institute
RV

About

Raja Velagapudi is an author at United States Food and Drug Administration specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

9

9

501

2

Pharmacology

7

7

147

3

Immunology

2

2

354

4

Education

1

1

13

5

Rheumatology

1

1

297

Raja Velagapudi

×

14

Publications

802

Citations

13

H-Index

YearCitations

Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: A pilot study

Michael H. Weisman, Larry W. Moreland, Daniel E. Furst,

Clinical Therapeutics

2003

297

A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis.

Alfons A den Broeder, Leo van de Putte, Rolf Rau,

PubMed

2002

195

A multicenter, open-label, prospective, randomized, dose-ranging pharmacokinetic study of the anti-TNF-α antibody afelimomab in patients with sepsis syndrome

James J. Gallagher, Charles J. Fisher, Bruce W. Sherman,

Intensive Care Medicine

2001

57

Phase I and Pharmacokinetic Study of LU79553, a DNA Intercalating Bisnaphthalimide, in Patients With Solid Malignancies

Miguel A. Villalona‐Calero, Joseph P. Eder, Deborah Toppmeyer,

Journal of Clinical Oncology

2001

37

Phase I and pharmacokinetic study of the water-soluble dolastatin 15 analog LU103793 in patients with advanced solid malignancies.

Miguel A. Villalona‐Calero, Sharyn D. Baker, L. A. Hammond,

Journal of Clinical Oncology

1998

32

A phase I clinical and pharmacokinetic study of the dolastatin analogue cemadotin administered as a 5-day continuous intravenous infusion

Jeffrey G. Supko, Thomas J. Lynch, Jeffrey W. Clark,

Cancer Chemotherapy and Pharmacology

2000

30

Harmonization of Regulatory Approaches for Evaluating Therapeutic Equivalence and Interchangeability of Multisource Drug Products: Workshop summary report

Mei‐Ling Chen, Vinod P. Shah, Daan J.A. Crommelin,

European Journal of Pharmaceutical Sciences

2011

26

Interactions of Apomorphine with Serum and Tissue Proteins

Robert V. Smith, Raja Velagapudi, Angus M. McLean,

Journal of Medicinal Chemistry

1985

26

Physiologically based absorption modeling to predict bioequivalence of controlled release and immediate release oral products

Amitava Mitra, Boštjan Petek, Aleksander Bajc,

European Journal of Pharmaceutics and Biopharmaceutics

2018

25

Clinical and pharmacologic phase I study of Cemadotin–HCl (LU103793), a novel antimitotic peptide, given as 24-hour infusion in patients with advanced cancer

K. Mross, Wolfgang E. Berdel, H.H. Fiebig,

Annals of Oncology

1998

23

Page 1